do stimulants calm children with adhd instead of making them more hyperactive?

“giving that to a kid who has severe ADHD, you would think would make them rem more rambunctious, less able to focus, and more distractable overall.”

a host, a neuroscientist said on Huberman Lab, 2026-10-01, at 34:12. hear it in context →

first, the part that holds

the speaker is right on the main point: in randomized trials, stimulants given to children with adhd lower hyperactivity and inattention ratings over the short term. they do not make those symptoms worse.

what we found when we went and looked

we read the two largest syntheses of the trials. a 2018 network meta-analysis in lancet psychiatry pooled 81 double-blind trials in children and adolescents. at 12 weeks, clinicians rated amphetamines at SMD -1.02 and methylphenidate at SMD -0.78 against placebo, and teachers rated methylphenidate at SMD -0.82. the 2023 cochrane review pooled 212 trials and found teacher-rated adhd symptoms improved by SMD -0.74, about 10.6 points on the adhd rating scale (the smallest difference that counts clinically is 6.6 points). cochrane graded that evidence very low certainty. the direction holds up, but the setup ("you would think it would make them more rambunctious") leaves something out: a 1978 trial in boys without adhd saw the same drop in motor activity and the same better test scores, so the calming effect is not unique to adhd.

assertion by assertion

both directions

for the speaker: two independent meta-analyses agree that stimulants beat placebo on adhd symptoms in children, whether clinicians or teachers do the rating. the cochrane estimate of about 10.6 points on the adhd rating scale is above the 6.6-point threshold for a difference that matters clinically. teacher-rated general behaviour also improved. none of the trial-level data we read shows stimulants raising hyperactivity on average in children with adhd. the 2018 meta-analysis concluded that methylphenidate is the preferred first choice for short-term treatment in children and adolescents.

against: first, certainty: cochrane rated the evidence for every outcome very low, mostly because of bias risk in the trials and unblinding from noticeable side effects, so the true size of the benefit is uncertain. second, time: the effects are measured at around 12 weeks. in the largest us treatment trial, the four randomized groups did not differ on 'nearly every analysis' 6 to 8 years later, and 'type or intensity of 14 months of treatment for adhd in childhood does not predict functioning 6 to 8 years later.' third, the counterintuitive framing: stimulants also lower motor activity and sharpen performance in boys without adhd, so the response is not a paradox unique to adhd. fourth, tolerability: on amphetamines, children and adolescents dropped out for side effects more often than on placebo (OR 2.30), and methylphenidate raised non-serious adverse events.

what this cannot say

we read abstracts, not the full trial data, and the abstract numbers are averages that hide individual variation. some children respond poorly, and these sources cannot say who. the trials mostly run weeks to months, and the long-term follow-up is observational after the randomized phase ended, with medication use down 62%, so it can neither confirm nor rule out a long-term benefit. the 1978 study of boys without adhd had 14 participants, used a single dose, and has not been replicated in the sources we read. we did not hear the full segment around 34:12, so we cannot say how the speaker framed the 'you would think' setup in context.

sources, each one fetched and read

1. Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727-738. doi:10.1016/S2215-0366(18)30269-4. PMID 30097390 What we read there: 133 double-blind RCTs (81 in children and adolescents). clinician-rated at 12 weeks: amphetamines SMD -1.02 (95% CI -1.19 to -0.85), methylphenidate -0.78 (-0.93 to -0.62). teacher-rated: only methylphenidate (SMD -0.82, -1.16 to -0.48) and modafinil more efficacious than placebo. amphetamines inferior to placebo on tolerability in children and adolescents (OR 2.30, 1.36-3.89). Fetched 2026-10-06 (HTTP 203). https://pubmed.ncbi.nlm.nih.gov/30097390/
2. Storebø OJ, Storm MRO, Pereira Ribeiro J, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev. 2023;3(3):CD009885. doi:10.1002/14651858.CD009885.pub3. PMID 36971690 What we read there: 212 trials, 16,302 participants. methylphenidate 'may improve teacher-rated ADHD symptoms (SMD -0.74, 95% CI -0.88 to -0.61; 21 trials; 1728 participants; very low-certainty evidence)', MD -10.58 on the ADHD-RS against a minimal clinically relevant difference of 6.6. teacher-rated general behaviour SMD -0.62 (-0.91 to -0.33). serious adverse events RR 0.80 (0.39 to 1.67). non-serious adverse events RR 1.23 (1.11 to 1.37). Fetched 2026-10-06 (HTTP 203). https://pubmed.ncbi.nlm.nih.gov/36971690/
3. Rapoport JL, Buchsbaum MS, Zahn TP, et al. Dextroamphetamine: cognitive and behavioral effects in normal prepubertal boys. Science. 1978. PMID 341313 What we read there: single dose of dextroamphetamine (0.5 mg/kg) vs placebo, double-blind, in 14 normal prepubertal boys: 'a marked decrease in motor activity and reaction time and improved performance on cognitive tests.' the similarity to responses in hyperactive children 'casts doubt on' models assuming 'a clinically specific or paradoxical response to stimulants.' Fetched 2026-10-06 (HTTP 203). https://pubmed.ncbi.nlm.nih.gov/341313/
4. Molina BSG, Hinshaw SP, Swanson JM, et al. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry. 2009;48(5):484-500. doi:10.1097/CHI.0b013e31819c23d0. PMID 19318991 What we read there: 'In nearly every analysis, the originally randomized treatment groups did not differ significantly.' 'Medication use decreased by 62% after the 14-month controlled trial.' 'Type or intensity of 14 months of treatment for ADHD in childhood does not predict functioning 6 to 8 years later.' Fetched 2026-10-06 (HTTP 203). https://pubmed.ncbi.nlm.nih.gov/19318991/

speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam